Divalproex Sodium Tablet, Extended Release
Product Images NDC 70518-1556

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 250mg 70518 1556 01

Divalproex Sodium Extended-Release 250 mg tablet bottle label showing 100 count. The label indicates the product is repackaged by RemedyRepack Inc. with NDC 70518-1556-01. It includes storage instructions and manufacturer information (Amneal Pharma). The label states the product is for prescription use only (RX ONLY).*

FDA Label Image

Divalproex Sodium 250mg 70518 1556 02

Divalproex Sodium 250 mg extended-release tablet label showing a quantity of 1 tablet. The labeler is RemedyRepack Inc., with manufacturing by Amneal Pharma, Bridgewater, NJ. The label includes NDC 70518-1556-02, storage instructions, and a QR code, indicating repackaging and directions to see the package insert for use.*

FDA Label Image

Remedy_label (Remedy Label)

Label of Divalproex Sodium extended-release tablets showing 250 mg strength in oral tablet form. The label indicates a quantity of 30 tablets and that the product is prescription only. Labeler is RemedyRepack Inc., with manufacturing information for Amneal Pharma in Bridgewater, NJ. Storage instructions and source NDC details are also provided.*

FDA Label Image

10 (Divalproex Sodium Extended Release Tablets Usp 1)

Chemical structure of divalproex sodium, showing the molecular arrangement including propyl groups, carboxylate, and sodium ion.*

FDA Label Image

Figure 1 (Divalproex Sodium Extended Release Tablets Usp 2)

A line graph comparing the percentage reduction in CPS rate for patients taking Divalproex Sodium versus placebo. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS rate, with improvement above zero and worsening below zero. The solid line indicates Divalproex Sodium, and the dashed line represents placebo, illustrating greater improvement in the Divalproex Sodium group.*

FDA Label Image

Figure 2 (Divalproex Sodium Extended Release Tablets Usp 3)

A cumulative distribution plot showing the percentage reduction in CPS rate versus the percentage of patients for Divalproex Sodium at high and low doses. The solid line represents high dose, and the dashed line represents low dose, with an axis indicating improvement versus worsening in CPS rate.*

FDA Label Image

Figure 3 (Divalproex Sodium Extended Release Tablets Usp 4)

A bar graph comparing the response values for Placebo and Divalproex Sodium Extended Release 250 mg oral tablets. The x-axis categorizes Placebo and Divalproex Sodium Extended Release, while the y-axis ranges from 0 to 1.2. The bar for Divalproex Sodium Extended Release is higher, reaching approximately 1.2, and includes a statistical significance marker with p=0.006.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.